Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.

Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L

Diabetes, obesity & metabolism28 Mar 2023Cited by 21 (Europe PMC)

PMID36869853DOI10.1111/dom.15045PepBankPUB-36869853

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, HbA1c fell by 1.2% points from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, HbA1c fell by 1.2 percentage points on weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n = 348
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2 % points
end of study
Source sentences
Summary
At EOS, mean changes were: HbA1c, -1.2% points [95% confidence interval (CI) -1.32; -1.10]
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, body weight fell by 4.7 kg from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, body weight fell by 4.7 kg on weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline to end of study
Study
n = 348
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Body weight change
−4.7 kg
end of study
Source sentences
Summary
BW, -4.7 kg (95% CI -5.38; -4.07)
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included change from baseline to EOS in body weight (BW) and waist circumference (WC); and proportion achieving HbA1c targets.
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985302
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, waist circumference fell by 4.9 cm from baseline to end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, waist size fell by 4.9 cm on weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference change from baseline to end of study
Study
n = 348
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Waist circumference change
−4.9 cm
end of study
Source sentences
Summary
WC, -4.9 cm (95% CI -5.94; -3.88).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary endpoints included change from baseline to EOS in body weight (BW) and waist circumference (WC); and proportion achieving HbA1c targets.
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985303
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, 81.7% reached an HbA1c below 8.0% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, 81.7% reached an HbA1c below 8.0% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with HbA1c <8.0% at end of study
Study
n = 348
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <8.0%
81.7%
end of study
Source sentences
Summary
At EOS, 81.7%, 67.7% and 51.6% of patients achieved an HbA1c target of <8.0%, <7.5% and <7.0%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985304
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, 67.7% reached an HbA1c below 7.5% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, 67.7% reached an HbA1c below 7.5% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with HbA1c <7.5% at end of study
Study
n = 348
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.5%
67.7%
end of study
Source sentences
Summary
At EOS, 81.7%, 67.7% and 51.6% of patients achieved an HbA1c target of <8.0%, <7.5% and <7.0%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985305
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in French routine practice, 51.6% reached an HbA1c below 7.0% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, 51.6% reached an HbA1c below 7.0% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with HbA1c <7.0% at end of study
Study
n = 348
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
51.6%
end of study
Source sentences
Summary
At EOS, 81.7%, 67.7% and 51.6% of patients achieved an HbA1c target of <8.0%, <7.5% and <7.0%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985306
07HumanObservational studySafety outcome
In adults with type 2 diabetes in French routine practice, no new safety concerns were identified with once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in French routine care, no new safety concerns were found with weekly semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSafety concerns
Study
n = 497
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
No new safety concerns were identified.
1 context sentence(design, population, supporting numbers)
Summary · context
This multicentre, prospective, open-label, single-arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation.
Report a problemFND-3686985307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04083820

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Novo Nordisk A/Sn = 52116 Sept 2019 to 27 Sept 2021

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 28 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.